Florida Healthcare Specialists的动态

This fantastic paper was published in the April issue of PPFO and is written by Lei et al. A valuable read on practical considerations for T-cell engagers in R/R MM.

Our 2024 Medical Pharmacy Trend Report includes six comprehensive oncology deep dives and shares insights on oncology biosimilars. Read our report to learn how biosimilars continue to impact medical pharmacy: https://bit.ly/3OfR8oD

Oncology infusions can be time-intensive for patients and care teams, but newer subcutaneous therapies like nivolumab and hyaluronidase-nvhy offer faster, more efficient options. TODAY at 2 pm EST: Join?Misty Simpson Deatherage, PharmD from?Bristol Myers Squibb, for an in-depth discussion on nivolumab and hyaluronidase-nvhy, a subcutaneous alternative to infusion therapies that offers a 3-5 minute administration time. Gain insight into its FDA approval, efficacy, dosing, safety, and potential adverse effects. Join here:?https://lnkd.in/eyeGJdGW

Approaching Ethical Dilemmas in Oncology Pharmacy: Karen Fancher, PharmD, BCOP, discusses some guiding principles for oncology pharmacists when facing ethical dilemmas and provides some recommendations for navigating those challenges. #finance #pharmacy #lifesciences

Going to PDA UPFS in Phoenix next week? AstraZeneca and Matchstick have again partnered with PDA - Parenteral Drug Association to present the Patient Pavilion at this year's conference. Our focus is a hot topic – SC oncology treatment with manual “syringe push” delivery. Join my friends and colleagues Sherri Biondi, Amy Rinaldi, Madeleine Anderson, Erin Araj, Alejandra Linares, Erika Bajars, Jenny Wu and Matt D'Auria at Booth 1029 as your schedule allows. I could not be prouder of what our team's put together. Take a self-guided walk-through or do a simulated injection activity when it works for your schedule as a walk-in. Or, sign up onsite for candid, small group discussions with our oncology patients, caregivers, and HCPs. (Register fast – last time, these booked up within a few hours). It's what you'd expect from a great collaboration – an immersive, empathetic experience through the users’ eyes, supported by rigorous research (about to be published in a peer-reviewed journal). Heart meets science – see you there.

Ecolab brings you the Bioquell Qube for cell and gene therapy…

Come learn about TIL therapy and earn FREE NCPD!

BREAKING: The FDA has approved tislelizumab-jsgr (Tevimbra) in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). https://lnkd.in/ea-nAcSr

What is the FDA Oncology Center of Excellence Project 5 in 5? OCE Director Dr. Richard Pazdur explains how ?????? can take part in crowdsourcing to ultimately select 5 clinically relevant questions to be answered in pragmatic clinical trials. https://lnkd.in/eQFkybsT #OCEProject5in5

From The Oncologist Journal -- Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model https://buff.ly/4cXq7Rb Prescription drug costs are a challenge for patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, aiming to provide transparently priced medications at reduced costs. This article describes the potential impact of MCCPDC on Medicare spending within oncology. #HealthCareCosts #CancerCare #FinancialToxicity